AMG National Trust Bank Trims Holdings in Stryker Co. (NYSE:SYK)

AMG National Trust Bank reduced its stake in Stryker Co. (NYSE:SYK - Free Report) by 17.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,854 shares of the medical technology company's stock after selling 3,502 shares during the quarter. AMG National Trust Bank's holdings in Stryker were worth $6,089,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. International Assets Investment Management LLC grew its holdings in shares of Stryker by 66,967.5% in the third quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company's stock worth $308,433,000 after purchasing an additional 852,496 shares during the last quarter. 1832 Asset Management L.P. grew its holdings in shares of Stryker by 146.9% in the first quarter. 1832 Asset Management L.P. now owns 878,669 shares of the medical technology company's stock worth $314,449,000 after purchasing an additional 522,817 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Stryker by 287.6% in the second quarter. American Century Companies Inc. now owns 505,608 shares of the medical technology company's stock worth $172,033,000 after purchasing an additional 375,166 shares during the last quarter. Canada Pension Plan Investment Board grew its holdings in shares of Stryker by 49.8% in the second quarter. Canada Pension Plan Investment Board now owns 686,416 shares of the medical technology company's stock worth $233,553,000 after purchasing an additional 228,139 shares during the last quarter. Finally, Sofinnova Investments Inc. bought a new position in shares of Stryker in the second quarter worth approximately $65,697,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SYK has been the topic of several recent analyst reports. BTIG Research lifted their price target on shares of Stryker from $383.00 to $394.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Barclays lifted their price target on shares of Stryker from $402.00 to $418.00 and gave the company an "overweight" rating in a report on Thursday, October 31st. StockNews.com upgraded shares of Stryker from a "hold" rating to a "buy" rating in a report on Thursday. Canaccord Genuity Group lifted their price target on shares of Stryker from $360.00 to $400.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Finally, Truist Financial lifted their price target on shares of Stryker from $370.00 to $380.00 and gave the company a "hold" rating in a report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, Stryker presently has an average rating of "Moderate Buy" and a consensus target price of $393.65.

Insider Activity

In other news, insider Viju Menon sold 600 shares of the company's stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares of the company's stock, valued at $3,219,495. This represents a 6.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP M Kathryn Fink sold 7,347 shares of the company's stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares of the company's stock, valued at $3,685,213.16. The trade was a 42.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 67,381 shares of company stock valued at $24,825,275 in the last quarter. 5.50% of the stock is currently owned by insiders.

Stryker Stock Down 0.2 %

Shares of SYK traded down $0.68 during trading hours on Monday, hitting $389.40. The company had a trading volume of 2,053,903 shares, compared to its average volume of 1,270,217. The firm has a fifty day moving average price of $364.61 and a 200-day moving average price of $347.98. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The stock has a market capitalization of $148.45 billion, a price-to-earnings ratio of 41.74, a P/E/G ratio of 2.94 and a beta of 0.91. Stryker Co. has a 52-week low of $285.79 and a 52-week high of $398.20.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. During the same quarter in the previous year, the firm earned $2.46 EPS. Stryker's revenue was up 11.9% on a year-over-year basis. On average, equities research analysts forecast that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.